[Non-mutilating treatment of breast cancer: survival and recurrence].
During the last decades considerable progress was made in medical and biomedical techniques, enabling early diagnosis and a better understanding of how tumors develop. At the same time, treatment by surgery has changed, becoming less and less mutilating. In order to analyze loco-regional relapses and factors of prognosis, we studied 420 patients representing 415 cases of breast cancer, all of whom received breast-preservation therapy. The case histories were followed from 1 to 17 1/2 years, with an average observation period of 4 years. The majority of patients underwent enlarged tumorectomy, generally accompanied by axillary dissection and by radiotherapy. Based on an overall study of our patients, actuarial survival was 87% after 5 years and 65% after 10 years. Not taking into consideration patients with tumors at stages pT3 and pT4 recovery was 90% after 5 and 67% after 10 years. We have attempted to demonstrate that this survival rate, as well as the occurrence of a relapse, vary according to different parameters, such as size and invasion of the axillary glands.
Cosendey
B A
BA
Service de chirurgie générale, CHUV, Lausanne.
Wellmann
D
D
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015412:Mastectomy, Segmental; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality*; D011183:Postoperative Complications / Q000401:mortality*; D015996:Survival Rate
Traitement non mutilant du cancer du sein: survie et récidives.